Live Breaking News & Updates on Pharma stocks

Stay informed with the latest breaking news from Pharma stocks on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Pharma stocks and stay connected to the pulse of your community

pharma stocks: Pramod Amthe is selective in midcaps; betting on 4 pharma stocks

The better way to play pharma is Sun Pharma and Aurobindo which we like. The other trend is domestic outlook for the growth for pharma. The proxy there is Torrent and Ajanta.Railways have new avenues of growth and strong momentum. Medium-term targets and government support improve growth prospects. Larger railway stocks like Concor, Kalpataru, and KEC are attractive due to their involvement in electrification lines. Having said that, some of the mid and smallcaps have run up much sharper.

Lucknow , Uttar-pradesh , India , Ajanta , Maharashtra , Kozhikode , Kerala , Bharat , Sun-pharma , Pramod-amthe , Cipla , Offering-college

Defensive bet with macro tailwinds? 5 Indian pharma stocks with upside potential of up to 20%

On Tuesday, when the whole market was reeling under pressure, two stocks reacted to their numbers in a positive direction. Both of them were large caps from one sector which is pharma. This becomes significant from three perspectives. First, that positive reaction was there on the day when there was a bloodbath on the street. Second, these stocks were already sitting on gains, so there is little probability of short covering leading to this sort of gains. Last but not the least it has come from sectors like pharma which have seen a very long phase of business remodelling and valuation readjustment, which makes it worth noticing. It might be too early to call, but if a re-rating gets momentum then they might be candidates for volatile markets.

Google , Market-research , Unlimited-access , Economic-times , Saver-sale , Membershipclaim-offer , Prime-story , Debit-cards , Includes-docubay , Economic-times-stories , Industry-trends

stock pick: Mileen Vasudeo on 2 pharma stocks to be on now

Mileen Vasudeo says: “Nifty is likely to head towards 22,300 to 22,500 levels. But yes, at lower levels like say 21,900, there is good support. Overall, the breadth of the market remains positive throughout the trading session. On the sector front, IT has really lifted the sentiments and the pharma pack is also looking good on the charts.”

Lucknow , Uttar-pradesh , India , Kozhikode , Kerala , Mileen-vasudeo , Vikas-nigam , Indian-school-of-business , Offering-college , Eicher-motors , Bajaj-auto , Senior-technical-research-analyst

Stock Radar: New 52-week high in Jan! Breakout from inverse Head & Shoulder pattern makes Divi's Labs an attractive buy

Short-term traders can look to buy the stock on decline up to Rs 4,000 levels, a crucial support and also closer to the neckline area of the inverse Head and shoulder pattern. An Inverse Head and shoulder pattern is the mirror image of the Head and Shoulder pattern and is a bullish signal.

Stock-radar , Pharma-stocks , Divi-rsquos-share-price , Divi-rsquos-labs-share-price , Divi-rsquos-labs , Divis-shares , Divis-laboratories ,

pharma stocks: Mayuresh Joshi on what to buy among PSU banks; 2 pharma stocks to buy on dips

Mayuresh Joshi says: “Sun Pharma, Cipla and Lupin probably remain as holds in our global portfolios. From an earnings perspective, Torrent Pharma and JV Chemicals on declines or pullbacks can probably be looked at. Again, the key triggers remain the same across both these stocks.” The comfort stays with largecaps from a valuation perspective as a whole host of mid/small caps have run up quite significantly.

Lucknow , Uttar-pradesh , India , Dahej , Gujarat , William-oneil , Mayuresh-joshi , Sun-pharma , Mayuresh-bank , Equity-research-india , Offering-college , Indian-school-of-business

Stocks to Buy | Midcaps | Smallcaps: Pankaj Pandey on his top 3 midcap and smallcap picks for 2024

Pankaj Pandey says: “Power as a space is looking quite good for the next five-seven year perspective and our sense is that the government focus will come back once the elections are out. So a lot of triggers are in placer for this sector to keep doing well. NTPC has already achieved a target price post result we will look at reviewing our target prices but NTPC remains top pick.”

Lucknow , Uttar-pradesh , India , Kalyan , Maharashtra , Kozhikode , Kerala , Varanasi , Ayodhya , Pankaj-pandey , Indusind-bank , Head-research

pharma stocks: Is Indian pharma sector priced to perfection? What will drive growth this year? Nithya Balasubramanian explains

Nithya Balasubramanian says: “At a top-down level, there is a lot more growth than what we are seeing in data. But I believe that the growth drivers will possibly shift into volume growth from pricing growth. The last two years have been pretty good in terms of pricing growth because of the higher inflation as well which was passed along.”

Lucknow , Uttar-pradesh , India , Kozhikode , Kerala , Sanford-bernstein , Nithya-balasubramanian , Cipla , Offering-college , Indian-school-of-business , Leadership-excellence , Product-officer

Getting back into shape? 6 Indian pharma stocks with upside potential of up to 41%

The year 2024, started with a correction in nifty, but one set of stocks which were able to outperform were pharma stocks. While it might appear to be a sudden up move, if one looks at what has happened in the pharma sector in the last eight years, there is a good chance that right from valuation readjustments to changing business model might play a role bringing the large pharma companies back into limelight. Infact some of these stocks have quietly inched upward in the last few months. It might be too early to call, but if a re-rating plays out in this space, it might surprise many in terms of price movement.

Google , Market-research , Unlimited-access , Economic-times , Saver-sale , Membershipclaim-offer , Prime-story , Debit-cards , Includes-docubay , Economic-times-stories , Industry-trends

stocks to buy: A pharma major and gaming stock for 6 to 8 % trading gains

While the markets have started to consolidate, traditionally defensive pockets like FMCG, Pharma, etc., have started to show improving relative strength and performance.

Stocks-to-buy , Stock-market , Stock-ideas , Pharma-stocks , Delta-corp , Cipla ,

Nifty Pharma hits all-time high; 10 stocks including Lupin, Cipla, Glenmark Pharma, Divi's Labs touch one-year peaks

In today's trade, Lupin's shares soared nearly 7%, hitting a new all-time high of ₹1,404 apiece after Japanese brokerage firm Nomura raised the target price on the stock to ₹1,593 apiece from the previous ₹1,290, maintaining its 'buy' recommendation.

India , United-states , Japan , Japanese , Prathamesh-masdekar , Sun-pharma , Motilal-oswal , Aurobindo-pharma , Zydus-lifesciences , Research-analyst-at-stoxbox , Glenmark-pharmaceuticals , Glaxosmithkline-pharmaceuticals